ABBV
Europe says yes
AbbVie just got the green light from the European Commission for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab, or R2, for adult patients with relapsed or refractory follicular lymphoma. In plain English: Europe just signed off on a chemotherapy-free option in a tough-to-treat blood cancer setting.
Why investors should perk up
This isn’t just regulatory paperwork dressed up as a press release. AbbVie says the combo is the first and only bispecific-based therapy approved in Europe for this indication, which gives it a nice little moat if the launch goes well. And because the approval is in the second-line setting, it opens the door to a meaningful slice of patients who need another option after earlier treatment.
The trial data did the talking
The nod came off the back of the Phase 3 EPCORE FL-1 trial, where fixed-duration TEPKINLY + R2 showed statistically significant improvement in progression-free survival and overall response rates versus R2 alone. AbbVie also says about three out of four patients hit a complete response, which is the kind of stat that makes oncologists nod and investors lean forward.
Big picture
For AbbVie, this is another reminder that the company is still trying to build a post-Humira future with a mix of immunology, oncology, and lots of regulatory chess moves. If TEPKINLY keeps stacking approvals like this, it could turn from promising pipeline piece into an actual revenue story — and that’s the kind of plot twist Wall Street loves.